

**CONFIDENTIAL**

### Single Site Analysis Result

PHYSICIAN	SPECIMEN	PATIENT
<b>John Smith, MD</b> <b>Comprehensive Medical Center</b> <b>1100 Grand Ave</b> <b>Away, GA 12345</b>	Specimen: <b>Blood</b> Draw date: <b>Aug 01, 2010</b> Accession date: <b>Aug 02, 2010</b> Report Date: <b>Aug 12, 2010</b>	Name: <b>Doe, Jane</b> Date of Birth: <b>April 1, 1492</b> Patient ID: <b>000000</b> Gender: <b>Female</b> Accession #: <b>00000000-BLD</b> Requisition #: <b>000000</b>

### Test Results and Interpretation

**POSITIVE FOR A DELETERIOUS MUTATION**

<u>Test Performed:</u> 198insC <i>MLH1</i>	<u>Result:</u> 198insC	<u>Interpretation:</u> <b>Deleterious</b>
---	---------------------------	--

This test is designed to detect the specific mutation(s) or variant(s) indicated above. The classification and interpretation of all variants identified in this assay reflects the current state of scientific understanding at the time this report was issued. In some instances, the classification and interpretation of such variants may change as new scientific information becomes available.

It is our understanding that this patient was identified for testing due to a personal or family history suggestive of Lynch syndrome (hereditary non-polyposis colorectal cancer, HNPCC). The results of this analysis are consistent with the germline *MLH1* mutation 198insC, resulting in premature truncation of the *MLH1* protein at amino acid position 78. Although the exact risk of cancer conferred by this specific mutation has not been determined, deleterious mutations in *MLH1* confer as much as an 82% risk of colorectal cancer and a 60% risk of endometrial cancer by age 70. Other increased cancer risks include as much as a 13% risk of gastric cancer and a 12% risk of ovarian cancer by age 70. (Vasen HFA et al. *Gastroenterology* 1996;110:1020-1027; Aarnio M et al. *International Journal of Cancer* 1999;81:214-218). First degree relatives of this individual each have a one-in-two chance of having this mutation. Family members can be tested for this specific mutation with a single site analysis.

Please contact Myriad Professional Support at 1-800-469-7423 to discuss any questions regarding this result.

\_\_\_\_\_  
Director Name Here  
Qualifications Here

\_\_\_\_\_  
Director Name Here  
Qualifications Here

These test results should only be used in conjunction with the patient's clinical history and any previous analysis of appropriate family members. It is strongly recommended that these test results be communicated to the patient in a setting that includes appropriate counseling. The accompanying Technical Specifications summary describes the analysis, method, performance characteristics, nomenclature, and interpretive criteria of this test. This test may be considered investigational by some states. This test and its performance characteristics were determined by Myriad Genetic Laboratories. It has not been reviewed by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.